Stacy Ann Coen - 29 Dec 2023 Form 4 Insider Report for ImmunoGen, Inc.

Role: SVP & CHIEF BUSINESS OFFICER
Signature: /s/ Renee Lentini, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 29 Dec 2023
Net transactions value: +$165,476
Form type: 4
Filing time: 03 Jan 2024, 17:51:50 UTC
Previous filing: 05 Dec 2023
Next filing: 13 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMGN	Common Stock	Options Exercise	$159,600	+30,000	+91%	$5.32	63,140	29 Dec 2023	Direct
transaction	IMGN	Common Stock	Award	$5,876	+367	+0.58%	$16.01	63,507	29 Dec 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMGN	Stock Option (Right to Buy)	Options Exercise	$0	-30,000	-9%	$0.000000	303,465	29 Dec 2023	Common Stock	30,000	$5.32	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from July 1, 2023 through December 31, 2023.
F2	In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 3, 2023
F3	This option was granted on February 4, 2022 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.